|
US5770700A
(en)
*
|
1996-01-25 |
1998-06-23 |
Genetics Institute, Inc. |
Liquid factor IX formulations
|
|
US6171586B1
(en)
*
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
US6991790B1
(en)
*
|
1997-06-13 |
2006-01-31 |
Genentech, Inc. |
Antibody formulation
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US6787523B1
(en)
*
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
EP2039368A3
(en)
|
1999-04-30 |
2009-04-01 |
La Jolla Institute For Allergy And Immunology |
Methods for preventing reactivation of latent virus and controlling virus replication
|
|
US7112576B1
(en)
|
1999-12-10 |
2006-09-26 |
Regents Of The University Of Minnesota |
Compositions and methods for cryopreservation of peripheral blood lymphocytes
|
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
JP4340062B2
(ja)
|
2000-10-12 |
2009-10-07 |
ジェネンテック・インコーポレーテッド |
粘度の減少した濃縮タンパク質製剤
|
|
US7083787B2
(en)
*
|
2000-11-15 |
2006-08-01 |
Globeimmune, Inc. |
Yeast-dendritic cell vaccines and uses thereof
|
|
TWI255272B
(en)
*
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
US20020141970A1
(en)
*
|
2001-03-05 |
2002-10-03 |
Pettit Dean K. |
Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
|
|
IL162618A0
(en)
*
|
2001-12-21 |
2005-11-20 |
Novo Nordisk As |
Liquid composition of modified factor vii polypeptides
|
|
BR0215216A
(pt)
*
|
2001-12-21 |
2004-11-16 |
Novo Nordisk Healthcare Ag |
Composição aquosa lìquida, método para preparar uma composição aquosa lìquida de um polipeptìdeo de fator vii, uso de uma composição aquosa lìquida, e, método para o tratamento de uma sìndrome de resposta ao fator vii
|
|
KR20040065278A
(ko)
*
|
2001-12-21 |
2004-07-21 |
노보 노르디스크 에이/에스 |
변경된 인자 ⅶ 폴리펩티드의 액체 조성물
|
|
DE10204792A1
(de)
*
|
2002-02-06 |
2003-08-14 |
Merck Patent Gmbh |
Lyophilisierte Zubereitung enthaltend Immuncytokine
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20040009918A1
(en)
*
|
2002-05-03 |
2004-01-15 |
Hanne Nedergaard |
Stabilised solid compositions of modified factor VII
|
|
ES2523655T5
(es)
|
2002-06-21 |
2018-04-23 |
Novo Nordisk Health Care Ag |
Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
PL378571A1
(pl)
*
|
2003-02-01 |
2006-05-02 |
Neuralab Limited |
Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß
|
|
RU2005132164A
(ru)
*
|
2003-03-18 |
2006-06-10 |
Ново Нордиск Хелт Кэр Аг (Ch) |
Жидкие, водные фармацевтические композиции полипептидов фактора vii
|
|
US7897734B2
(en)
*
|
2003-03-26 |
2011-03-01 |
Novo Nordisk Healthcare Ag |
Method for the production of proteins
|
|
EP2335725B1
(en)
*
|
2003-04-04 |
2016-10-12 |
Genentech, Inc. |
High concentration antibody and protein formulations
|
|
KR20060015574A
(ko)
|
2003-05-23 |
2006-02-17 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
용액 중 단백질 안정화
|
|
TWI374893B
(en)
*
|
2003-05-30 |
2012-10-21 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
ES2382157T3
(es)
*
|
2003-06-25 |
2012-06-05 |
Novo Nordisk Health Care Ag |
Composición líquida de polipépttidos del factor VII
|
|
JP5306597B2
(ja)
*
|
2003-07-01 |
2013-10-02 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
第ｖｉｉ因子ポリペプチドの液体水性薬学的組成物
|
|
CN102872451A
(zh)
*
|
2003-08-14 |
2013-01-16 |
诺和诺德医疗保健公司 |
因子vii多肽类的含水液体药物组合物
|
|
ATE507822T1
(de)
|
2003-12-19 |
2011-05-15 |
Novo Nordisk Healthcare Ag |
Stabilisierte zusammensetzungen von faktor-vii- polypeptiden
|
|
US7425539B2
(en)
|
2004-03-19 |
2008-09-16 |
Baxter International Inc. |
Factor IXa for the treatment of bleeding disorders
|
|
ES2390082T5
(es)
*
|
2004-06-30 |
2018-01-19 |
Nektar Therapeutics |
Conjugados de resto de Factor IX y polímeros
|
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
|
TW200635607A
(en)
|
2004-12-15 |
2006-10-16 |
Elan Pharm Inc |
Humanized Aβ antibodies for use in improving cognition
|
|
WO2006066049A2
(en)
*
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
|
EP1838349A1
(en)
*
|
2004-12-15 |
2007-10-03 |
Neuralab, Ltd. |
Amyloid beta antibodies for use in improving cognition
|
|
GT200600031A
(es)
*
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
BRPI0606867A2
(pt)
*
|
2005-01-28 |
2009-07-21 |
Wyeth Corp |
formulação lìquida; forma de dosagem unitária farmacêutica; kit; recipiente; método para aumentar a estabilidade de um polipeptìdeo de ligação a antìgeno numa formulação; método para preparar uma forma de dosagem unitária farmacêutica; formulação estável; formulação; e produto terapêutico
|
|
EP1913159B1
(en)
*
|
2005-06-30 |
2010-12-01 |
GE Healthcare Bio-Sciences Corp. |
Detection method for gene expression
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
US7608261B2
(en)
|
2006-06-16 |
2009-10-27 |
Regeneron Pharmacuticals, Inc. |
VEGF antagonist formulations suitable for intravitreal administration
|
|
AU2007234612B2
(en)
|
2006-12-14 |
2013-06-27 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein stabilization formulations
|
|
US8449520B2
(en)
*
|
2007-03-19 |
2013-05-28 |
HemCon Medical Technologies Inc. |
Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
KR101578561B1
(ko)
|
2007-04-26 |
2015-12-17 |
바이엘 헬스케어 엘엘씨 |
냉동 저장을 위한, 재조합 단백질의 액상 용액의 안정화
|
|
CA2687246A1
(en)
*
|
2007-06-01 |
2008-12-11 |
Acologix, Inc. |
High temperature stable peptide formulation
|
|
US7678764B2
(en)
|
2007-06-29 |
2010-03-16 |
Johnson & Johnson Regenerative Therapeutics, Llc |
Protein formulations for use at elevated temperatures
|
|
DK2182983T3
(da)
|
2007-07-27 |
2014-07-14 |
Janssen Alzheimer Immunotherap |
Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
|
|
CN101801405A
(zh)
|
2007-08-07 |
2010-08-11 |
先进科技及再生医学有限责任公司 |
包含于酸性水溶液中的gdf-5的蛋白质配方
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
US7947649B2
(en)
*
|
2008-04-14 |
2011-05-24 |
Advanced Technologies And Regenerative Medicine, Llc |
Liquid buffered GDF-5 formulations
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
SG174258A1
(en)
|
2009-03-06 |
2011-10-28 |
Genentech Inc |
Antibody formulation
|
|
AU2011219612A1
(en)
*
|
2010-02-24 |
2012-09-06 |
Arecor Limited |
Stable compositions of Factor IX
|
|
DK3345615T3
(da)
|
2010-03-01 |
2020-01-20 |
Bayer Healthcare Llc |
Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi)
|
|
US8613919B1
(en)
|
2012-08-31 |
2013-12-24 |
Bayer Healthcare, Llc |
High concentration antibody and protein formulations
|
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
|
JP6553020B2
(ja)
*
|
2013-03-15 |
2019-07-31 |
ジーピービー デット ホールディングス トゥー エルエルシー |
アレルギー及び自己免疫疾患に関する診断分析を行うための自動化された免疫分析計システム
|
|
TWI745671B
(zh)
|
2013-03-15 |
2021-11-11 |
美商百歐維拉提夫治療公司 |
因子ｉｘ多肽調配物
|
|
EA038573B1
(ru)
|
2014-03-24 |
2021-09-16 |
Биовератив Терапьютикс Инк. |
Лиофилизированный состав, содержащий фактор ix, для предупреждения приступов кровотечения
|
|
HRP20231379T1
(hr)
|
2015-12-03 |
2024-02-16 |
Regeneron Pharmaceuticals, Inc. |
Postupci dovođenja u vezu genskih varijanti s kliničkim ishodom kod pacijenata koji pate od starosne makularne degeneracije liječenih anti-vegf-om
|
|
EP3694322B1
(en)
|
2017-10-09 |
2024-07-03 |
Terumo BCT Biotechnologies, LLC |
Lyophilization container and method of using same
|
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
|
JP7471316B2
(ja)
|
2019-03-14 |
2024-04-19 |
テルモ ビーシーティー バイオテクノロジーズ，エルエルシー |
マルチパート凍結乾燥容器
|